Juventas Therapeutics has completed a Phase I clinical trial for its lead product, JVS-100, to evaluate safety and efficacy in the treatment of patients with Class III heart failure. The Phase I trial demonstrated that JVS-100 is well tolerated with no adverse effects. Further, patients demonstrated significant improvements in key functional parameters. Following the success of Phase I, Juventas has received US FDA authorization to commence two Phase II studies to test JVS-100 efficacy in heart failure and critical limb ischemia patients, respectfully. Juventas is presently enrolling its Phase II studies. For more information please contact Joe Pastore at jpastore@juventasinc.com.

Participating Clinical Trial Sites:
Critical Limb Ischemia: 
Cardiology P.C. – Birmingham, Alabama 
Minneapolis Heart Institute – Minneapolis, Minnesota 
Montefiore Medical Center – Bronx, New York
Northwestern University – Chicago, Illinois 
Summa Health System – Akron, Ohio
Medanta – India 
Sir Ganga Ram Hospital – India

Heart Failure: 
Cardiology, P.C. – Birmingham, Alabama
The Christ Hospital, Lindner Center for Research – Cincinnati, Ohio
Columbia University – New York, New York
Minneapolis Heart Institute – Minneapolis, Minnesota
Montefiore Medical Center – Bronx, New York
Summa Health System – Akron, Ohio
University of Florida – Gainesville, Florida
University of Pennsylvania – Philadelphia, Pennsylvania
University of South Florida / Pepin Heart Institute – Tampa, Florida
University of Utah – Salt Lake City, Utah